SCLERO.ORG
Search

Cyclophosphamide and Revimmune for Systemic Scleroderma

Cyclophosphamide for Systemic Scleroderma Lung Disease, Pulmonary Fibrosis, Alveolitis, and Skin Fibrosis

Author: Shelley Ensz. Scleroderma is highly variable. See Types of Scleroderma. Read Disclaimer
SCOT Clinical Trial
SCOT Substudy 01
Northwestern University Clinical Trials
Scleroderma Lung Study II
Cyclophosphamide Research
Also see

SCOT Clinical Trial: This study has been completed.

SCOT Clinical Trial, which stands for "Scleroderma Cyclophosphamide Or Transplantation", will compare two potential therapies: autologous stem cell transplantation versus high-dose monthly cyclophosphamide. Study dates 2005-2017. ClinicalTrials.gov. (Also see Scleroderma Clinical Trials: Current and Stem Cell Transplantation)

SCOT Substudy 01 Clinical Trial (By invitation only)

Scleroderma: Cyclophosphamide or Transplantation (SCOT) Substudy 01. The primary purpose of this study is to determine the plasma concentration and exposure time required for cyclosphosphamide to produce optimal immunosuppressive activity with minimal toxicity in subjects with severe systemic sclerosis. This study is currently enrolling participants by invitation only. ClinicalTrials.gov.

Northwestern University Clinical Trials

Allogeneic Hematopoietic Stem Cell Transplantation (NST) for Patients With Systemic Sclerosis. This study is designed to examine whether treating patients with high dose Cyclophosphamide and Fludarabine (drugs which reduce the function of your immune system) and CAMPATH-1H (a protein that kills the immune cells that are thought to be causing the disease), followed by return of blood stem cells that have been previously collected from patients brother or sister will stop or reverse the disease. This study is currently recruiting participants. (Northwestern) ClinicalTrials.gov.

Cyclophosphamide and rATG With Hematopoietic Stem Cell Support in Systemic Scleroderma. To evaluate the efficacy (phase II) of two treatment modalities: pulse cyclophosphamide versus high dose cyclophosphamide and rATG rescued with autologous peripheral blood stem cell transplantation. This study is currently recruiting participants. (Northwestern). ClinicalTrials.gov. Contact information: [email protected] and tel 1-312-908-0059.

Scleroderma Lung Study I: Postitive Results with Oral Cyclophosphamide

Systemic Sclerosis (SSc) Sera Impair Angiogenic Performance of Dermal Microvascular Endothelial Cells: Therapeutic Implications of Cyclophosphamide (CYC). In SSc, CYC treatment might boost angiogenesis and consequently improve peripheral microangiopathy through the normalization of the endothelial cell-matrix interactions, reduction of endothelial cell apoptosis and rebalance of dysregulated angiostatic factors. PubMed, PLoS One, 2015 Jun 15;10(6):e0130166.

Results from the Scleroderma Lung Study I. This study showed that 1 year of oral cyclophosphamide (CYC) was effective in improving lung function, symptoms of shortness of breath, and quality of life but the effect on lung function and quality of life only lasted for another 6 months after CYC was stopped. UCLA.

Scleroderma Lung Study II

Scleroderma Lung Study II.

Scleroderma Lung Study II. This study compares 2 different medications—daily oral cyclophosphamide (CYC) with daily oral mycophenolate mofetil (MMF, also called Cellcept™) in the treatment of scleroderma-related pulmonary fibrosis. There are twelve study centers across the U.S. This study is currently recruiting. University of California, Los Angeles. November 2009. (Also see Pulmonary Fibrosis, Cellcept, Cyclophosphamide, and Clinical Trials)

Cyclophosphamide Research for Systemic Sclerosis (Scleroderma)

Cyclophosphamide for connective tissue disease–associated interstitial lung disease. Researchers may consider comparing cyclophosphamide (a potent immunosuppressant) versus antifibrotic agents, or comparing both versus placebo, in particular, for those with evidence of rapidly progressive fibrotic disease, who may benefit the most. PubMed, Cochrane Database Syst Rev, 2018 Jan 3;1:CD010908. (Also see Treatments for Pulmonary Fibrosis)

Also See

Pulmonary Fibrosis. ISN.

Scleroderma Medical News. ISN.

Systemic Scleroderma Symptoms (Main list; treatments are listed on each symptom page.) ISN.

Scleroderma Treatments and Clinical Trials. ISN.

Skin Fibrosis. ISN.

Go to Clinical Trials,Habeo Cell Therapy
 

See ISN News for recent donors, including donations in memory of Peter J. Devlin. Click Here to Donate.

 

TOLL FREE HOTLINE, U.S. and Canada: 1-800-564-7099
Ask for our Free Info Packet by email or postal mail!

SCLERO.ORG is the world's leading nonprofit for trustworthy research, support, education and awareness for scleroderma and related illnesses.

We are a service of the nonprofit International Scleroderma Network (ISN), which is a 501(c)(3) U.S.-based public charitable foundation, established in 2002. Meet Our Team, or Volunteer. Donations may also be mailed to:

International Scleroderma Network (ISN)
7455 France Ave So #266
Edina, MN 55435-4702 USA
Email [email protected] to request our Welcome email, report bad links, or update page content. Disclaimer. Privacy Policy.
 

The most important thing in the world to know about scleroderma is sclero.org!